3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Pleural Effusion, Malignant
2
Mesothelioma, Malignant
2
Breast Neoplasms
2
Recurrence
1
Rare Malignant Neoplasm
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Lymphoma
1
Lymphedema
1
Immunoglobulin Light-chain Amyloidosis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gynecological Cancers
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Dysplastic Nevus Syndrome
1
Complicated Adrenal Tumor Diseases
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
BRAF V600 Colorectal Cancer
1
Anxiety Disorders
1
Interventions
Temozolomide
16
Irinotecan
13
Cyclophosphamide
11
dinutuximab
9
naxitamab
7
Vincristine
7
Carboplatin
6
sargramostim
5
Melphalan
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Etoposide
5
fludarabine
4
Topotecan
4
Thiotepa
4
Eflornithine
4
Doxorubicin
4
Cisplatin
4
etoposide phosphate
3
Zoledronic Acid
3
Specimen Handling
3
Isotretinoin
3
Granulocyte Colony-Stimulating Factor
3
saponin QA-21V1
2
lutetium Lu 177 dotatate
2
aldesleukin
2
Vorinostat
2
Stem Cell Transplantation
2
Radiation
2
Platinum
2
Mesna
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroblastoma
×
Pharmaceutical Preparations
×
Clear all
NCT07334301
2026-01-12
BEACON2
University of Birmingham
Phase 1/2
Recruiting
160 enrolled